Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BRD2 | P25440 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785147 | 1.00 | — | — | |
| SCHEMBL1123 | 1.00 | — | — | |
| SCHEMBL4653374 | 0.96 | — | — | |
| Ammonia Solution, Strong SCHEMBL1914672 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL3984605 | 0.96 | — | — | |
| SCHEMBL25175816 | 0.96 | — | — | |
| SCHEMBL21409686 | 0.96 | — | — | |
| SCHEMBL21409789 | 0.96 | — | — | |
| SCHEMBL21409683 | 0.96 | — | — | |
| SCHEMBL23174460 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113777298-A | Latex enhanced immunosuppression method kit for rapidly detecting glycocholic acid, preparation method and detection method | 美康生物科技股份有限公司 | 2021-12-10 | — | — | CN | disclosed |
| CN-112730844-A | Teicoplanin detection reagent composition, and preparation method and application thereof | 上海云泽生物科技有限公司 | 2021-04-30 | — | — | CN | disclosed |
| CN-109983026-A | Mixed mode affinity chromatography carrier | 富士胶片株式会社 | 2019-07-05 | — | — | CN | disclosed |
| CN-109833648-A | Vomitoxin and its derivative aptamers affinity column and the preparation method and application thereof | 北京农业质量标准与检测技术研究中心 | 2019-06-04 | — | — | CN | disclosed |
| CN-109675061-A | Nano material and its preparation method and application | 中国农业科学院特产研究所 | 2019-04-26 | — | — | CN | disclosed |
| CN-108139371-A | The purification process of affinity chromatography carrier and biological substance | 富士胶片株式会社 | 2018-06-08 | — | — | CN | disclosed |
| CN-107531799-A | The manufacture method and short-chain peptide fixation support of short-chain peptide fixation support | 富士胶片株式会社 | 2018-01-02 | — | — | CN | disclosed |
| CN-107501547-A | A kind of phenyl boric acid functionalization amphion block copolymer and glucose-sensitive bionic nano carrier | 吉林建筑大学 | 2017-12-22 | — | — | CN | disclosed |
| US-9394237-B2 | β-substituted β-amino acids and analogs as chemotherapeutic agents | QUADRIGA BIOSCIENCES, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150218086-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. | 2015-08-06 | — | — | US | disclosed |
| US-8097702-B2 | Modified human interferon polypeptides with at least one non-naturally encoded amino acid and their uses | AMBRX, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110020359-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURONAL DAMAGE OR DEGENERATION | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2011-01-27 | — | — | US | disclosed |
| US-20080108791-A1 | Cytokine polypeptide for use in treatment and prevention of viral and cell proliferative disorders | AMBRX, INC. (US) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108791-A1 | Cytokine polypeptide for use in treatment and prevention of viral and cell proliferative disorders | IL2, HDGF, IFNG | KDM4E 4880/4885GAA 357/4885POLB 417/4885 |
| US-20150218086-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | SLC7A1, SLC3A2, SLC1A5 | KDM4E 4338/4885GAA 1356/4885POLB 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.